Market Research Logo

Helicobacter Pylori Infections - Pipeline Review, H2 2015

Helicobacter Pylori Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Helicobacter Pylori Infections - Pipeline Review, H2 2015’, provides an overview of the Helicobacter Pylori Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Helicobacter Pylori Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Helicobacter Pylori Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Helicobacter Pylori Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Helicobacter Pylori Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Helicobacter Pylori Infections Overview
Therapeutics Development
Pipeline Products for Helicobacter Pylori Infections - Overview
Pipeline Products for Helicobacter Pylori Infections - Comparative Analysis
Helicobacter Pylori Infections - Therapeutics under Development by Companies
Helicobacter Pylori Infections - Therapeutics under Investigation by Universities/Institutes
Helicobacter Pylori Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Helicobacter Pylori Infections - Products under Development by Companies
Helicobacter Pylori Infections - Products under Investigation by Universities/Institutes
Helicobacter Pylori Infections - Companies Involved in Therapeutics Development
Daewoong Pharmaceutical Co., Ltd.
EpiVax, Inc.
ImevaX GmbH
ImmunoBiology Limited
RedHill Biopharma Ltd.
Sequella, Inc.
Shanghai Zerun Biotechnology Co., Ltd.
Sigmoid Pharma Limited
Helicobacter Pylori Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(rifabutin + amoxicillin sodium + omeprazole sodium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWJ-1325 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FROST-900 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Helicobacter pylori [Hel-305] (multivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPi-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Helicobacter Pylori Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SQ-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Helicobacter Pylori Infections - Recent Pipeline Updates
Helicobacter Pylori Infections - Dormant Projects
Helicobacter Pylori Infections - Product Development Milestones
Featured News & Press Releases
Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection
Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection
Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study
Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results
May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study
Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection
Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment
Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105
Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
Dec 23, 2013: RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Helicobacter Pylori Infections, H2 2015
Number of Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Helicobacter Pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Helicobacter Pylori Infections - Pipeline by EpiVax, Inc., H2 2015
Helicobacter Pylori Infections - Pipeline by ImevaX GmbH, H2 2015
Helicobacter Pylori Infections - Pipeline by ImmunoBiology Limited, H2 2015
Helicobacter Pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2015
Helicobacter Pylori Infections - Pipeline by Sequella, Inc., H2 2015
Helicobacter Pylori Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2015
Helicobacter Pylori Infections - Pipeline by Sigmoid Pharma Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Helicobacter Pylori Infections Therapeutics - Recent Pipeline Updates, H2 2015
Helicobacter Pylori Infections - Dormant Projects, H2 2015
Helicobacter Pylori Infections - Dormant Projects (Contd..1), H2 2015
List of Figures
Number of Products under Development for Helicobacter Pylori Infections, H2 2015
Number of Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report